InflaRx (NASDAQ:IFRX) Shares Bought by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. grew its holdings in shares of InflaRx (NASDAQ:IFRX) by 18.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 317,859 shares of the company’s stock after purchasing an additional 48,944 shares during the quarter. Raymond James Financial Services Advisors Inc. owned approximately 0.71% of InflaRx worth $518,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IFRX. 683 Capital Management LLC boosted its position in shares of InflaRx by 17.5% during the 3rd quarter. 683 Capital Management LLC now owns 2,350,000 shares of the company’s stock valued at $7,003,000 after acquiring an additional 350,000 shares during the last quarter. Alps Advisors Inc. boosted its position in shares of InflaRx by 109.4% during the 3rd quarter. Alps Advisors Inc. now owns 83,279 shares of the company’s stock valued at $248,000 after acquiring an additional 43,501 shares during the last quarter. Raymond James & Associates boosted its position in shares of InflaRx by 18.5% during the 3rd quarter. Raymond James & Associates now owns 162,406 shares of the company’s stock valued at $484,000 after acquiring an additional 25,350 shares during the last quarter. Affinity Asset Advisors LLC boosted its position in shares of InflaRx by 35.3% during the 3rd quarter. Affinity Asset Advisors LLC now owns 325,097 shares of the company’s stock valued at $969,000 after acquiring an additional 84,897 shares during the last quarter. Finally, Invesco Ltd. boosted its position in shares of InflaRx by 42.2% during the 1st quarter. Invesco Ltd. now owns 226,610 shares of the company’s stock valued at $415,000 after acquiring an additional 67,214 shares during the last quarter. Institutional investors and hedge funds own 42.39% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of InflaRx in a research report on Friday, March 22nd.

InflaRx Trading Up 7.1 %

Shares of IFRX opened at $1.35 on Friday. The firm has a market cap of $79.49 million, a P/E ratio of -1.57 and a beta of 1.27. InflaRx has a 12-month low of $1.14 and a 12-month high of $5.20. The company’s 50-day moving average price is $1.56 and its 200 day moving average price is $1.64.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). Equities research analysts forecast that InflaRx will post -1 earnings per share for the current year.

InflaRx Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.